Resection and survival data from a clinical trial of glioblastoma multiforme‐specific IRDye800‐BBN fluorescence‐guided surgery

Abstract Supra‐maximum surgical tumor resection without neurological damage is highly valuable for treatment and prognosis of patients with glioblastoma multiforme (GBM). We developed a GBM‐specific fluorescence probe using IRDye800CW (peak absorption/emission, 778/795 nm) and bombesin (BBN), which...

Full description

Bibliographic Details
Main Authors: Kunshan He, Chongwei Chi, Deling Li, Jingjing Zhang, Gang Niu, Fangqiao Lv, Junmei Wang, Wenqiang Che, Liwei Zhang, Nan Ji, Zhaohui Zhu, Jie Tian, Xiaoyuan Chen
Format: Article
Language:English
Published: Wiley 2021-01-01
Series:Bioengineering & Translational Medicine
Subjects:
Online Access:https://doi.org/10.1002/btm2.10182
id doaj-d51e5c1a8eb94da0a3ef65383f9b33ec
record_format Article
spelling doaj-d51e5c1a8eb94da0a3ef65383f9b33ec2021-10-08T14:05:41ZengWileyBioengineering & Translational Medicine2380-67612021-01-0161n/an/a10.1002/btm2.10182Resection and survival data from a clinical trial of glioblastoma multiforme‐specific IRDye800‐BBN fluorescence‐guided surgeryKunshan He0Chongwei Chi1Deling Li2Jingjing Zhang3Gang Niu4Fangqiao Lv5Junmei Wang6Wenqiang Che7Liwei Zhang8Nan Ji9Zhaohui Zhu10Jie Tian11Xiaoyuan Chen12Beijing Advanced Innovation Center for Big Data‐Based Precision Medicine Beihang University Beijing ChinaCAS Key Laboratory of Molecular Imaging, Institute of Automation Chinese Academy of Sciences Beijing ChinaDepartment of Neurosurgery, Beijing Tiantan Hospital Capital Medical University Beijing ChinaDepartment of Nuclear Medicine, Peking Union Medical College Hospital Chinese Academy of Medical Sciences and Peking Union Medical College Beijing ChinaLaboratory of Molecular Imaging and Nanomedicine (LOMIN) National Institute of Biomedical Imaging and Bioengineering (NIBIB), National Institutes of Health (NIH) Bethesda Maryland USADepartment of Cell Biology, School of Basic Medical Sciences Capital Medical University Beijing ChinaDepartment of Neuropathology, Beijing Neurosurgical Institute Capital Medical University Beijing ChinaDepartment of Neurosurgery, Beijing Tiantan Hospital Capital Medical University Beijing ChinaDepartment of Neurosurgery, Beijing Tiantan Hospital Capital Medical University Beijing ChinaDepartment of Neurosurgery, Beijing Tiantan Hospital Capital Medical University Beijing ChinaDepartment of Nuclear Medicine, Peking Union Medical College Hospital Chinese Academy of Medical Sciences and Peking Union Medical College Beijing ChinaBeijing Advanced Innovation Center for Big Data‐Based Precision Medicine Beihang University Beijing ChinaLaboratory of Molecular Imaging and Nanomedicine (LOMIN) National Institute of Biomedical Imaging and Bioengineering (NIBIB), National Institutes of Health (NIH) Bethesda Maryland USAAbstract Supra‐maximum surgical tumor resection without neurological damage is highly valuable for treatment and prognosis of patients with glioblastoma multiforme (GBM). We developed a GBM‐specific fluorescence probe using IRDye800CW (peak absorption/emission, 778/795 nm) and bombesin (BBN), which (IRDye800‐BBN) targets the gastrin‐releasing peptide receptor, and evaluated the image‐guided resection efficiency, sensitivity, specificity, and survivability. Twenty‐nine patients with newly diagnosed GBM were enrolled. Sixteen hours preoperatively, IRDye800‐BBN (1 mg in 20 ml sterile water) was intravenously administered. A customized fluorescence surgical navigation system was used intraoperatively. Postoperatively, enhanced magnetic resonance images were used to assess the residual tumor volume, calculate the resection extent, and confirm whether complete resection was achieved. Tumor tissues and nonfluorescent brain tissue in adjacent noneloquent boundary areas were harvested and assessed for diagnostic accuracy. Complete resection was achieved in 82.76% of patients. The median extent of resection was 100% (range, 90.6–100%). Eighty‐nine samples were harvested, including 70 fluorescence‐positive and 19 fluorescence‐negative samples. The sensitivity and specificity of IRDye800‐BBN were 94.44% (95% CI, 85.65–98.21%) and 88.24% (95% CI, 62.25–97.94%), respectively. Twenty‐five patients were followed up (median, 13.5 [3.1–36.0] months), and 14 had died. The mean preoperative and immediate and 6‐month postoperative Karnofsky performance scores were 77.9 ± 11.8, 71.3 ± 19.2, and 82.6 ± 14.7, respectively. The median overall and progression‐free survival were 23.1 and 14.1 months, respectively. In conclusion, GBM‐specific fluorescent IRDye800‐BBN can help neurosurgeons identify the tumor boundary with sensitivity and specificity, and may improve survival outcomes.https://doi.org/10.1002/btm2.10182fluorescent IRDye800‐BBNgliomaintraoperativeneurosurgeryprognosis
collection DOAJ
language English
format Article
sources DOAJ
author Kunshan He
Chongwei Chi
Deling Li
Jingjing Zhang
Gang Niu
Fangqiao Lv
Junmei Wang
Wenqiang Che
Liwei Zhang
Nan Ji
Zhaohui Zhu
Jie Tian
Xiaoyuan Chen
spellingShingle Kunshan He
Chongwei Chi
Deling Li
Jingjing Zhang
Gang Niu
Fangqiao Lv
Junmei Wang
Wenqiang Che
Liwei Zhang
Nan Ji
Zhaohui Zhu
Jie Tian
Xiaoyuan Chen
Resection and survival data from a clinical trial of glioblastoma multiforme‐specific IRDye800‐BBN fluorescence‐guided surgery
Bioengineering & Translational Medicine
fluorescent IRDye800‐BBN
glioma
intraoperative
neurosurgery
prognosis
author_facet Kunshan He
Chongwei Chi
Deling Li
Jingjing Zhang
Gang Niu
Fangqiao Lv
Junmei Wang
Wenqiang Che
Liwei Zhang
Nan Ji
Zhaohui Zhu
Jie Tian
Xiaoyuan Chen
author_sort Kunshan He
title Resection and survival data from a clinical trial of glioblastoma multiforme‐specific IRDye800‐BBN fluorescence‐guided surgery
title_short Resection and survival data from a clinical trial of glioblastoma multiforme‐specific IRDye800‐BBN fluorescence‐guided surgery
title_full Resection and survival data from a clinical trial of glioblastoma multiforme‐specific IRDye800‐BBN fluorescence‐guided surgery
title_fullStr Resection and survival data from a clinical trial of glioblastoma multiforme‐specific IRDye800‐BBN fluorescence‐guided surgery
title_full_unstemmed Resection and survival data from a clinical trial of glioblastoma multiforme‐specific IRDye800‐BBN fluorescence‐guided surgery
title_sort resection and survival data from a clinical trial of glioblastoma multiforme‐specific irdye800‐bbn fluorescence‐guided surgery
publisher Wiley
series Bioengineering & Translational Medicine
issn 2380-6761
publishDate 2021-01-01
description Abstract Supra‐maximum surgical tumor resection without neurological damage is highly valuable for treatment and prognosis of patients with glioblastoma multiforme (GBM). We developed a GBM‐specific fluorescence probe using IRDye800CW (peak absorption/emission, 778/795 nm) and bombesin (BBN), which (IRDye800‐BBN) targets the gastrin‐releasing peptide receptor, and evaluated the image‐guided resection efficiency, sensitivity, specificity, and survivability. Twenty‐nine patients with newly diagnosed GBM were enrolled. Sixteen hours preoperatively, IRDye800‐BBN (1 mg in 20 ml sterile water) was intravenously administered. A customized fluorescence surgical navigation system was used intraoperatively. Postoperatively, enhanced magnetic resonance images were used to assess the residual tumor volume, calculate the resection extent, and confirm whether complete resection was achieved. Tumor tissues and nonfluorescent brain tissue in adjacent noneloquent boundary areas were harvested and assessed for diagnostic accuracy. Complete resection was achieved in 82.76% of patients. The median extent of resection was 100% (range, 90.6–100%). Eighty‐nine samples were harvested, including 70 fluorescence‐positive and 19 fluorescence‐negative samples. The sensitivity and specificity of IRDye800‐BBN were 94.44% (95% CI, 85.65–98.21%) and 88.24% (95% CI, 62.25–97.94%), respectively. Twenty‐five patients were followed up (median, 13.5 [3.1–36.0] months), and 14 had died. The mean preoperative and immediate and 6‐month postoperative Karnofsky performance scores were 77.9 ± 11.8, 71.3 ± 19.2, and 82.6 ± 14.7, respectively. The median overall and progression‐free survival were 23.1 and 14.1 months, respectively. In conclusion, GBM‐specific fluorescent IRDye800‐BBN can help neurosurgeons identify the tumor boundary with sensitivity and specificity, and may improve survival outcomes.
topic fluorescent IRDye800‐BBN
glioma
intraoperative
neurosurgery
prognosis
url https://doi.org/10.1002/btm2.10182
work_keys_str_mv AT kunshanhe resectionandsurvivaldatafromaclinicaltrialofglioblastomamultiformespecificirdye800bbnfluorescenceguidedsurgery
AT chongweichi resectionandsurvivaldatafromaclinicaltrialofglioblastomamultiformespecificirdye800bbnfluorescenceguidedsurgery
AT delingli resectionandsurvivaldatafromaclinicaltrialofglioblastomamultiformespecificirdye800bbnfluorescenceguidedsurgery
AT jingjingzhang resectionandsurvivaldatafromaclinicaltrialofglioblastomamultiformespecificirdye800bbnfluorescenceguidedsurgery
AT gangniu resectionandsurvivaldatafromaclinicaltrialofglioblastomamultiformespecificirdye800bbnfluorescenceguidedsurgery
AT fangqiaolv resectionandsurvivaldatafromaclinicaltrialofglioblastomamultiformespecificirdye800bbnfluorescenceguidedsurgery
AT junmeiwang resectionandsurvivaldatafromaclinicaltrialofglioblastomamultiformespecificirdye800bbnfluorescenceguidedsurgery
AT wenqiangche resectionandsurvivaldatafromaclinicaltrialofglioblastomamultiformespecificirdye800bbnfluorescenceguidedsurgery
AT liweizhang resectionandsurvivaldatafromaclinicaltrialofglioblastomamultiformespecificirdye800bbnfluorescenceguidedsurgery
AT nanji resectionandsurvivaldatafromaclinicaltrialofglioblastomamultiformespecificirdye800bbnfluorescenceguidedsurgery
AT zhaohuizhu resectionandsurvivaldatafromaclinicaltrialofglioblastomamultiformespecificirdye800bbnfluorescenceguidedsurgery
AT jietian resectionandsurvivaldatafromaclinicaltrialofglioblastomamultiformespecificirdye800bbnfluorescenceguidedsurgery
AT xiaoyuanchen resectionandsurvivaldatafromaclinicaltrialofglioblastomamultiformespecificirdye800bbnfluorescenceguidedsurgery
_version_ 1716838308676370432